Cansu Döndü Üsküdar, Teke Hava Üsküdar, Korkmaz Cengiz
Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, Eskisehir, Turkey.
Division of Hematology, Eskişehir Osmangazi University, Eskisehir, Turkey.
Rheumatol Int. 2017 Aug;37(8):1381-1385. doi: 10.1007/s00296-017-3687-4. Epub 2017 Mar 2.
In rheumatology practice, anti-tumor necrosis factor (TNF) alpha agents are frequently used medications, more so in ankylosing spondylitis (AS). There are case reports, besides their adverse effects, such as infection and injection site reaction, suggesting these agents may cause solid or hematologic malignancies. Acute leukemia secondary to anti-TNF alpha agents has been rarely reported in patients with AS. In this case report, based on a patient who developed acute leukemia while on the treatment with etanercept, we will discuss whether it is possible to predict acute leukemia by monitoring the mean corpuscular volume in light of the literature.
在风湿病临床实践中，抗肿瘤坏死因子（TNF）α药物是常用药物，在强直性脊柱炎（AS）治疗中使用更为频繁。有病例报告显示，除感染和注射部位反应等不良反应外，这些药物可能会引发实体瘤或血液系统恶性肿瘤。抗TNFα药物继发急性白血病在AS患者中鲜有报道。在本病例报告中，基于一名在使用依那西普治疗期间发生急性白血病的患者，我们将结合文献探讨通过监测平均红细胞体积来预测急性白血病是否可行。
